TrialJAMA2022

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

Meagan P O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.